Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats
出版年份 2018 全文链接
标题
Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats
作者
关键词
-
出版物
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 32, Issue 5, Pages 578-590
出版商
SAGE Publications
发表日期
2018-03-01
DOI
10.1177/0269881118756061
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model
- (2017) Ashleigh L Osborne et al. NEUROPSYCHOPHARMACOLOGY
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Neurocognition: Clinical and Functional Outcomes in Schizophrenia
- (2017) Martin Lepage et al. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
- Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
- (2016) Rajaa El Bekay et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
- (2016) Pelle L. Ishøy et al. DIABETES OBESITY & METABOLISM
- Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist
- (2016) Kenichi Katsurada et al. Journal of Diabetes Investigation
- Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients
- (2015) Ping Feng et al. ACTA PHARMACOLOGICA SINICA
- Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials
- (2015) R. E. Nielsen et al. ACTA PSYCHIATRICA SCANDINAVICA
- Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice
- (2015) Paula L. McClean et al. BEHAVIOURAL BRAIN RESEARCH
- Exercise prevents downregulation of hippocampal presynaptic proteins following olanzapine-elicited metabolic dysregulation in rats: Distinct roles of inhibitory and excitatory terminals
- (2015) A. Ramos-Miguel et al. NEUROSCIENCE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
- (2015) Marcus Lind et al. BMJ-British Medical Journal
- Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
- (2015) Marcus Lind et al. BMJ-British Medical Journal
- Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System
- (2015) Jennifer E. Richard et al. PLoS One
- Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice
- (2015) Kanako Tamura et al. PLoS One
- Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
- (2014) Helena M. de Wit et al. DIABETOLOGIA
- Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior
- (2014) Rozita H. Anderberg et al. PHYSIOLOGY & BEHAVIOR
- Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
- (2014) Fares Bassil et al. PROGRESS IN NEUROBIOLOGY
- Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice
- (2014) David Cheng et al. PSYCHOPHARMACOLOGY
- Impact of Antipsychotic Treatment on Attention and Motor Learning Systems in First-Episode Schizophrenia
- (2014) Sarah K. Keedy et al. SCHIZOPHRENIA BULLETIN
- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
- (2014) Pelle L Ishøy et al. BMJ Open
- Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
- (2013) Pelle L. Ishøy et al. AMERICAN JOURNAL OF PSYCHIATRY
- Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor
- (2013) Katrina Weston-Green et al. CNS DRUGS
- Circuit mechanisms of GluA1-dependent spatial working memory
- (2013) Florian Freudenberg et al. HIPPOCAMPUS
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
- (2013) Christian Hölscher JOURNAL OF ENDOCRINOLOGY
- Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
- (2013) Paula L. McClean et al. NEUROPHARMACOLOGY
- Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats
- (2013) A.M. Barr et al. NEUROSCIENCE
- Diabetes and Cognitive Deficits in Chronic Schizophrenia: A Case-Control Study
- (2013) Mei Han et al. PLoS One
- Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals
- (2013) M Bomba et al. Cell Death & Disease
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Schizophrenia Is a Cognitive Illness
- (2013) René S. Kahn et al. JAMA Psychiatry
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- (2012) Kerry Hunter et al. BMC NEUROSCIENCE
- Relationship between metabolic syndrome and cognition in patients with schizophrenia
- (2012) Jean Pierre Lindenmayer et al. SCHIZOPHRENIA RESEARCH
- Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4
- (2011) Song Chen et al. AGE
- Neuroprotective properties of GLP-1: theoretical and practical applications
- (2011) Jens Juul Holst et al. CURRENT MEDICAL RESEARCH AND OPINION
- GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake
- (2011) Amber L. Alhadeff et al. ENDOCRINOLOGY
- Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels
- (2011) Katrina Weston-Green et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
- (2011) P. L. McClean et al. JOURNAL OF NEUROSCIENCE
- Effects of olanzapine and clozapine on memory acquisition, consolidation and retrieval in mice using the elevated plus maze test
- (2011) Oguz Mutlu et al. NEUROSCIENCE LETTERS
- Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats
- (2010) Katrina Weston-Green et al. BEHAVIOURAL BRAIN RESEARCH
- Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance
- (2010) D. W. Porter et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis
- (2010) V L Albaugh et al. MOLECULAR PSYCHIATRY
- The Antipsychotics Olanzapine, Risperidone, Clozapine and Haloperidol Are D2-Selective Ex Vivo but Not In Vitro
- (2010) Patrick N McCormick et al. NEUROPSYCHOPHARMACOLOGY
- A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model
- (2010) Heidi N. Boyda et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
- (2010) Carol Kilkenny et al. PLOS BIOLOGY
- Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
- (2009) S. M. Stahl et al. ACTA PSYCHIATRICA SCANDINAVICA
- Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease
- (2009) Talib Abbas et al. BEHAVIOURAL BRAIN RESEARCH
- Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system
- (2009) Alison Hamilton et al. NEUROREPORT
- Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat
- (2008) G. C. Smith et al. DIABETOLOGIA
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine
- (2008) Nima Davoodi et al. PSYCHOPHARMACOLOGY
- The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
- (2008) Kirsten Lykkegaard et al. SCHIZOPHRENIA RESEARCH
- d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats
- (2007) Jun-ichi Karasawa et al. BEHAVIOURAL BRAIN RESEARCH
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
- Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain
- (2007) G.D. Cooper et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now